Gossamer Bio vs Tango Therapeutics
Tango Therapeutics is the larger business, with $62.4m of revenue in fiscal 2025 against $48.5m for Gossamer Bio (1.3 times as much). Tango Therapeutics grew faster (48.3% against -57.7%). Tango Therapeutics kept more of each dollar of sales as profit: a net margin of -162.9% against -351.5%.
| Latest fiscal year | Gossamer BioGOSS, 2025 | Tango TherapeuticsTNGX, 2025 |
|---|---|---|
| Revenue | $48.5m | $62.4m |
| Revenue growth | -57.7% | 48.3% |
| Net income | −$170m | −$102m |
| Operating margin | -352.2% | — |
| Net margin | -351.5% | -162.9% |
| Return on equity | — | -37.2% |
| Free cash flow | −$171m | −$140m |
| Cash | $37.7m | $112m |
| Total debt | $0 | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 161 | 137 |
| Market value | $4.62bn | $3.66bn |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 25 sales |